Continued progress across pipeline programs with focus on pancreatic cancer
Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS
Bolstered cash position provides runway to fund operations for approximately 12 months
OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE:AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2025.
“Through the second quarter, we continued to prioritize and accelerate our development efforts for Ampligen, particularly in our Phase 2 trial for locally advanced pancreatic cancer in collaboration with Erasmus Medical Center and AstraZeneca. We remain encouraged by the growing body of positive clinical data demonstrated to date and believe that as we build momentum, we are well positioned to execute on a clear path toward government approval. Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers, and our mission remains focused on making a meaningful difference in this space for patients,” commented AIM Chief Executive Officer Thomas K. Equels.
Recent Highlights
- Resumed trading on the NYSE American;
- Closed public equity offering in July, raising $8.0 million in gross proceeds, which is expected to fund operations for approximately 12 months;
- Reported positive data in a mid-year update from …